Phase 3
-
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Phase 3 · randomised · 800 people · 285 sites in 17 countries · Recruiting now
-
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
Phase 3 · randomised · 550 people · 2 sites in China · Opening soon
-
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
Phase 3 · randomised · 901 people · 133 sites in 16 countries · Running, not taking new patients
-
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation
Phase 3 · randomised · 461 people · 419 sites in 32 countries · Running, not taking new patients
-
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
Phase 3 · randomised · 250 people · 113 sites in 2 countries · Recruiting now
-
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Phase 3 · randomised · 408 people · 62 sites in United States · Recruiting now
-
Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment
Phase 3 · randomised · 244 people · 4 sites in France · Recruiting now
-
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Phase 3 · randomised · 450 people · 291 sites in 35 countries · Recruiting now
-
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Phase 3 · randomised · 700 people · 35 sites in 8 countries · Recruiting now
-
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer
Phase 3 · randomised · 1,020 people · 21 sites in 6 countries · Recruiting now